Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (CADL) is a Massachusetts-based biotechnology company, also known as Advantagene, Inc., specializing in the development of cutting-edge immuno-oncology platforms aimed at treating solid tumors. The company's focus is on leveraging the body's immune system to combat cancer through innovative viral immunotherapies.
At the core of Candel Therapeutics' technology are two proprietary platforms: the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform. Designed as an 'off-the-shelf' solution, GMCI™ aims to generate a personalized and precise immune response against cancer, utilizing the patient's own immune system. The RQNestin34.5 platform, on the other hand, is centered around the use of genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.
As a clinical-stage biopharmaceutical company, Candel Therapeutics is dedicated to translating its scientific advancements into viable treatments for patients. The company has made substantial progress with its platforms, demonstrating promising results in clinical studies aiming to establish the efficacy and safety of these novel therapies.
Among the company's recent highlights is its presentation at the American Society of Clinical Oncology (ASCO), where it shared significant updates on its ongoing projects. Candel Therapeutics continues to engage in strategic partnerships and collaborations to advance its mission of making effective cancer treatments accessible to patients globally.
Candel Therapeutics is committed to maintaining robust investor relations, offering transparent updates and clear communication about its financial health, project milestones, and future directions. The company's leadership frequently engages with stakeholders to ensure alignment with their goals and expectations.
For the latest news and detailed financial information, investors and interested parties can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com or Kyle Evans, Account Director at ICR Westwicke, at CandelPR@westwicke.com.
Bionaut Labs and Candel Therapeutics have formed a strategic collaboration to advance preclinical development of remote-controlled microscale robots for targeted delivery of oncolytic viral immunotherapies to brain tumors. Utilizing Bionaut’s precision medicine technology, the partnership aims to enhance therapeutic efficacy for high-grade glioma patients. Both companies will retain rights to their platforms while working together towards clinical trials. Terms of the agreement remain undisclosed.
Candel Therapeutics (Nasdaq: CADL) announced a collaboration with the Partnership for Accelerating Cancer Therapies (PACT) for a biomarker analysis in a phase 2 clinical trial targeting non-small cell lung cancer (NSCLC). The study will evaluate the efficacy of CAN-2409 combined with immune checkpoint inhibitors following inadequate responses to initial treatments. With three patient cohorts, the collaboration aims to identify early biological indicators of treatment response. This partnership enhances Candel's research credibility and aims to advance therapeutic options for cancer patients.
Candel Therapeutics (Nasdaq: CADL) presented encouraging data from its phase 1 trial of CAN-3110 at the SITC Annual Meeting. This oncolytic virus therapy showed significant T-cell infiltration and immune activation in patients with recurrent high-grade glioma. Preliminary data previously reported at ASCO indicated an overall survival of 11.7 months. The histological analysis confirmed persistence of viral antigens and a strong immune response, suggesting the potential of CAN-3110 to improve treatment outcomes for patients with this challenging cancer.
Candel Therapeutics (Nasdaq: CADL) reported its Q3 financial results, announcing a net loss of $16.2 million for the quarter, a substantial increase from $2.6 million in Q3 2020. Cash reserves as of September 30, 2021, stood at $88.4 million, bolstered by an IPO in August 2021. Research and development expenses surged to $5.3 million from $1.8 million year-over-year, attributed to increased clinical trial activities. The company remains on track to fund operations into Q2 2023, with several clinical presentations highlighting advancements in its oncolytic viral therapies, CAN-2409 and CAN-3110.
On November 2, 2021, Candel Therapeutics, Inc. (Nasdaq: CADL) announced that CEO Paul Peter Tak will speak at several investor conferences in November.
- Credit Suisse 30th Annual Healthcare Conference: Fireside Chat on November 8, 2021, at 11:20 am ET.
- BMO Biopharma Spotlight Series: Panel Discussion on November 8, 2021, at 12:45 pm ET.
- Jefferies London Healthcare Conference: Fireside Chat on November 17, 2021, at 1:00 pm GMT.
For more information and webcasts, visit Candel's website.
Candel Therapeutics (Nasdaq: CADL) announced its participation in key medical conferences, including the 13th International Oncolytic Virus Conference and the 26th Annual Meeting of the Society for Neuro-Oncology. Presentations will focus on their oncolytic viral immunotherapies, CAN-3110 and CAN-2409, with insights into their trial data. Notably, CAN-2409 targets high-grade gliomas and shows promise in combination therapies. The events are scheduled for November 5, 6, and 19, 2021, with additional details available on Candel's website.
Candel Therapeutics (Nasdaq: CADL) presented tolerability data from its phase 3 clinical trial of CAN-2409 for localized prostate cancer at the 28th Annual Prostate Cancer Foundation Scientific Retreat on October 28, 2021. The trial involved 745 patients, with over 2,000 injection procedures performed. Results showed 65% of patients found transperineal injections equally or better tolerated than biopsies, while 89% reported the same for transrectal injections. Overall, 100% felt positive about their participation. This supports the treatment's promise, potentially improving outcomes while reducing the need for long-term androgen deprivation therapy.
Candel Therapeutics (Nasdaq: CADL) appointed Dr. Mace L. Rothenberg as a senior advisor to CEO Paul Peter Tak. Dr. Rothenberg, a seasoned medical executive with over 30 years in government and industry, previously served as Chief Medical Officer at Pfizer, where he played a crucial role in the development of several cancer therapies and the COVID-19 vaccine. His expertise is expected to support Candel's growth and enhance its oncology drug pipeline, particularly in advancing their lead candidates, CAN-2409 and CAN-3110, through clinical trials.
Candel Therapeutics, Inc. (Nasdaq: CADL) announced its participation in the SITC 36th Annual Meeting, where it will present novel biomarker data from its phase 1 clinical trial of CAN-3110 for recurrent high-grade glioma. The presentation, titled 'Detection of viral antigen and immune activation after intra-tumor injection of CAN-3110', will take place on November 12, 2021. CAN-3110 is designed to selectively kill cancer cells while sparing healthy ones, with promising results recently shared at the ASCO Annual Meeting. More information is available on their website.
Candel Therapeutics, a late-stage biopharmaceutical firm, announced that its CEO Paul Peter Tak and investigator E. Antonio Chiocca will present data on oncolytic viral immunotherapies for glioblastoma at two conferences on Oct. 6 and 27, 2021. The presentations will cover novel therapies CAN-2409 and CAN-3110, focusing on their mechanisms and clinical trial results. CAN-2409 targets a wide range of solid tumors while CAN-3110 is under investigation for recurrent high-grade glioma. More details are available on Candel's website.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
What does Candel Therapeutics, Inc. specialize in?
What are the main platforms developed by Candel Therapeutics?
How does the GMCI™ platform work?
What is unique about the RQNestin34.5 platform?
Is Candel Therapeutics a clinical-stage company?
What recent achievements has Candel Therapeutics made?
Who can I contact for investor relations at Candel Therapeutics?
Who handles media inquiries for Candel Therapeutics?
What types of cancer are targeted by Candel Therapeutics' platforms?
Where is Candel Therapeutics based?
